Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study

Claire N Harrison, Ruben Mesa, Moshe Talpaz, Haifa Kathrin Al-Ali, Blanca Xicoy, Francesco Passamonti, Francesca Palandri, Giulia Benevolo, Alessandro M. Vannucchi, Clemence Mediavilla, Alessandra Iurlo, InHo Kim, Patrick Brown, Christopher Hernandez, Shelonitda Rose, Jia Wang, Jean-Jacques Kiladjian

Blood (2023) 142 (Supplement 1): 3204.

https://doi.org/10.1182/blood-2023-173391

Published: 2023

Journal Articles

Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial

Danny Jeyaraju, Sheida Hayati, Jia Wang, Claire N Harrison, Jean-Jacques Kiladjian, Christopher Hernandez, Patrick Brown, Daniel Lopes De Menezes, Anita K. Gandhi, Rajasekhar N.V.S. Suragani

Blood (2023) 142 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2023-180419

Published: 2023

Journal Articles

Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

Blood (2022) 139 (12): 1785–1793.

https://doi.org/10.1182/blood.2021012328

Published: 2022

Includes: Supplemental data

Journal Articles

How I treat infant leukemia

Patrick Brown, Rob Pieters, Andrea Biondi

Blood (2019) 133 (3): 205–214.

https://doi.org/10.1182/blood-2018-04-785980

Published: 2019

Journal Articles

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Blood (2018) 132 (Supplement 1): 261.

https://doi.org/10.1182/blood-2018-99-116948

Published: 2018

Journal Articles

Whole Genome Bisulfite Sequencing (WGBS) Robustly Measures the Pharmacodynamic Effect of Decitabine/Vorinostat Epigenetic Treatment in Relapsed Pediatric ALL Demonstrating Potent Hypomethylation Associated with Upregulation of PRC2 and TP53 Targets

Rumen Kostadinov, PhD, Byunggil Yoo, MS, Midhat S. Farooqi, MD PhD, Shannon Kelley, MS, Erin Guest, MD, Michael J. Burke, MD, Sarah Wheelan, MD PhD, Patrick Brown, MD

Blood (2018) 132 (Supplement 1): 918.

https://doi.org/10.1182/blood-2018-99-119206

Published: 2018

Journal Articles

Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331

Laura Brook Hogan, MD, Teena Bhatla, MD, Sue Rheingold, MD, Lingyun Ji, PhD, Xinxin Xu, Elizabeth A. Raetz, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD, Patrick Brown, MD

Blood (2018) 132 (Supplement 1): 1382.

https://doi.org/10.1182/blood-2018-99-112269

Published: 2018

Journal Articles

Blinatumomab for MRD + B-ALL: the evidence strengthens

Patrick Brown

Blood (2018) 131 (14): 1497–1498.

https://doi.org/10.1182/blood-2018-02-830364

Published: 2018

Journal Articles

Genomic Analysis and Pathway Characterization of Genes with Somatic Variants in Infant Acute Lymphoblastic Leukemia

Jillian Fry, Midhat S. Farooqi, MD PhD, Byunggil Yoo, MS, Rumen Kostadinov, PhD, Emily Farrow, PhD CGC, Shannon Kelley, MS, Margaret Gibson, Neil Miller, Jeffrey Johnston, Patrick Brown, MD, Erin Guest, MD

Blood (2017) 130 (Supplement 1): 3970.

https://doi.org/10.1182/blood.V130.Suppl_1.3970.3970

Published: 2017

Journal Articles

Differential Expression of Adhesion Molecule Receptors May Influence Bone Marrow Microenvironment-Mediated Protection of Leukemia-Initiating Cells (LICs) in Infant MLL- rearranged ( MLL- R) Acute Lymphoblastic Leukemia (ALL)

Edward Allan R. Sison, MD, Amos S. Gaikwad, PhD, Gaye Jenkins, Terzah M. Horton, MD PhD, Patrick Brown, MD, Michele S. Redell, MD PhD

Blood (2016) 128 (22): 1585.

https://doi.org/10.1182/blood.V128.22.1585.1585

Published: 2016

Journal Articles

Landscape of Somatic Mutations and Gene Expression Changes in Relapsed Infant MLL-Rearranged Acute Lymphoblastic Leukemia

Rumen Kostadinov, PhD, Midhat Farooqi, MD PhD, Byunggil Yoo, MS, Emily Farrow, PhD CGC, Shannon Kelley, Margaret Gibson, Neil Miller, Erin M. Guest, MD, Patrick Brown, MD

Blood (2016) 128 (22): 1735.

https://doi.org/10.1182/blood.V128.22.1735.1735

Published: 2016

Journal Articles

High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials

Blood (2016) 128 (22): 2803.

https://doi.org/10.1182/blood.V128.22.2803.2803

Published: 2016

Journal Articles

Proteomic/Transcriptomic Signatures of Infant MLL-r Rearranged B-ALL at Diagnosis and Relapse Reveal Lineage Plasticity and Diagnostic Heterogeneity

Jevon Cutler, Raiha Tahir, Rumen Kostadinov, PhD, Raja Sekhar, PhD, Tai-Chung Huang, MD PhD, Akhilesh Pandey, MD PhD, Patrick Brown, MD, Mohammad Heydarian, PhD, Karen Reddy, PhD

Blood (2016) 128 (22): 2697.

https://doi.org/10.1182/blood.V128.22.2697.2697

Published: 2016

Journal Articles

Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia

Neerav Shukla, MD, Cynthia Wetmore, MD PhD, Maureen M O'Brien, MD, Lewis B. Silverman, MD, Patrick Brown, MD, Todd M Cooper, DO, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Ben Suttle, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Lia Gore, MD

Blood (2016) 128 (22): 2780.

https://doi.org/10.1182/blood.V128.22.2780.2780

Published: 2016

Journal Articles

Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Michael J. Burke, MD, Patrick Brown, MD, Richard Sposto, PhD, Lia Gore, MD, Alan S. Wayne, MD

Blood (2016) 128 (22): 2781.

https://doi.org/10.1182/blood.V128.22.2781.2781

Published: 2016

Journal Articles

Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG)

Blood (2016) 128 (22): 758.

https://doi.org/10.1182/blood.V128.22.758.758

Published: 2016

Journal Articles

Targeting BCL6-Mediated Resistance to BCR-ABL Targeted Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) through the Addition of Histone Deacetylase (HDAC) Inhibitors

Gordon Cohen, MD MPH, Colleen E. Annesley, MD, Rachel E. Rau, MD, Shannon Kelley, Daniel Magoon, Patrick Brown, MD

Blood (2015) 126 (23): 1277.

https://doi.org/10.1182/blood.V126.23.1277.1277

Published: 2015

Journal Articles

Differential Signaling through p190 and p210 Forms of BCR-ABL Fusion Proteins Revealed By Proteomic Analysis

Jevon Cutler, Rahia Tahir, Jingnan Han, Raja Sekhar Nirujogi, Tai-Chung Huang, MD, Xianrong Wong, Saradhi Mallampati, Xiaoping Sun, MD PhD, Patrick Brown, MD, Karen Reddy, PhD, Akhilesh Pandey, MD PhD

Blood (2015) 126 (23): 3651.

https://doi.org/10.1182/blood.V126.23.3651.3651

Published: 2015

Journal Articles

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Neerav Shukla, MD, Maureen M. O'Brien, MD, Lewis B. Silverman, MD, Melinda Pauly, MD, Cynthia Wetmore, MD PhD, Mignon L. Loh, MD, James A. Whitlock, MD, Patrick Brown, MD, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Patricia Pimentel, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Richard Koche, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Lia Gore, MD

Blood (2015) 126 (23): 3792.

https://doi.org/10.1182/blood.V126.23.3792.3792

Published: 2015

Journal Articles

A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations

Colleen E. Annesley, MD, Amy S. Duffield, MD PhD, Rachel E. Rau, MD, Gregory McCarty, Daniel Magoon, Li Li, MD PhD, Vicki Huff, PhD, Donald Small, MD PhD, David Loeb, MD PhD, Patrick Brown, MD

Blood (2015) 126 (23): 312.

https://doi.org/10.1182/blood.V126.23.312.312

Published: 2015

NARROW

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study

Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial

Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

How I treat infant leukemia

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Whole Genome Bisulfite Sequencing (WGBS) Robustly Measures the Pharmacodynamic Effect of Decitabine/Vorinostat Epigenetic Treatment in Relapsed Pediatric ALL Demonstrating Potent Hypomethylation Associated with Upregulation of PRC2 and TP53 Targets

Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331

Blinatumomab for MRD + B-ALL: the evidence strengthens

Genomic Analysis and Pathway Characterization of Genes with Somatic Variants in Infant Acute Lymphoblastic Leukemia

Differential Expression of Adhesion Molecule Receptors May Influence Bone Marrow Microenvironment-Mediated Protection of Leukemia-Initiating Cells (LICs) in Infant MLL- rearranged ( MLL- R) Acute Lymphoblastic Leukemia (ALL)

Landscape of Somatic Mutations and Gene Expression Changes in Relapsed Infant MLL-Rearranged Acute Lymphoblastic Leukemia

Proteomic/Transcriptomic Signatures of Infant MLL-r Rearranged B-ALL at Diagnosis and Relapse Reveal Lineage Plasticity and Diagnostic Heterogeneity

Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia

Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG)

Targeting BCL6-Mediated Resistance to BCR-ABL Targeted Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) through the Addition of Histone Deacetylase (HDAC) Inhibitors

Differential Signaling through p190 and p210 Forms of BCR-ABL Fusion Proteins Revealed By Proteomic Analysis

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only